Barclays Reiterates an 'Overweight' on Array BioPharma (ARRY); Reports FY2Q11, Data for MEK inhibitors in 2011
Tweet Send to a Friend
Barclays reiterates an 'Overweight' on Array BioPharma (NASDAQ: ARRY), PT $10.
Barclays analyst says, "We are reiterating our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are reiterating our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
